XTLB – X.T.L. Biopharmaceuticals Ltd. ADR
XTLB — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
1.57
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
Price
2.88
Target Price
6
Analyst Recom
1
Performance Q
10.11
Upside
N/A
Beta
1.4
Ticker: XTLB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | XTLB | 2.895 | N/A | N/A | 0 |
| 2026-07-14 | XTLB | 2.9 | N/A | N/A | 0 |
| 2026-07-15 | XTLB | 2.95 | N/A | N/A | 0 |
| 2026-07-16 | XTLB | 2.86 | N/A | N/A | 0 |
| 2026-07-17 | XTLB | 2.85 | N/A | N/A | 0 |
| 2026-07-20 | XTLB | 2.86 | N/A | N/A | 0 |
| 2026-07-21 | XTLB | 2.86 | N/A | N/A | 0 |
| 2026-07-22 | XTLB | 2.92 | N/A | N/A | 0 |
| 2026-07-23 | XTLB | 2.78 | N/A | N/A | 0 |
| 2026-07-24 | XTLB | 2.86 | N/A | N/A | 0 |
| 2026-07-27 | XTLB | 2.87 | N/A | N/A | 0 |
| 2026-07-28 | XTLB | 2.79 | N/A | N/A | 0 |
| 2026-07-29 | XTLB | 2.96 | N/A | N/A | 0 |
| 2026-07-30 | XTLB | 2.81 | N/A | N/A | 0 |
| 2026-07-31 | XTLB | 2.82 | N/A | N/A | 0 |
| 2026-08-03 | XTLB | 2.77 | N/A | N/A | 0 |
| 2026-08-04 | XTLB | 2.8799 | N/A | N/A | 0 |
| 2026-08-05 | XTLB | 2.87 | N/A | N/A | 0 |
| 2026-08-07 | XTLB | 2.8 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | XTLB | 2.81 | - | - | - |
| 2026-07-14 | XTLB | 2.91 | - | - | - |
| 2026-07-15 | XTLB | 2.92 | - | - | - |
| 2026-07-16 | XTLB | 2.89 | - | - | - |
| 2026-07-17 | XTLB | 2.88 | - | - | - |
| 2026-07-20 | XTLB | 2.76 | - | - | - |
| 2026-07-21 | XTLB | 2.95 | - | - | - |
| 2026-07-22 | XTLB | 2.92 | - | - | - |
| 2026-07-23 | XTLB | 2.92 | - | - | - |
| 2026-07-24 | XTLB | 2.81 | - | - | - |
| 2026-07-27 | XTLB | 2.87 | - | - | - |
| 2026-07-28 | XTLB | 2.93 | - | - | - |
| 2026-07-29 | XTLB | 2.80 | - | - | - |
| 2026-07-30 | XTLB | 2.81 | - | - | - |
| 2026-07-31 | XTLB | 2.75 | - | - | - |
| 2026-08-03 | XTLB | 2.80 | - | - | - |
| 2026-08-04 | XTLB | 2.80 | - | - | - |
| 2026-08-05 | XTLB | 2.88 | - | - | - |
| 2026-08-06 | XTLB | 2.80 | - | - | - |
| 2026-08-07 | XTLB | 2.88 | - | - | - |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | XTLB | 0.00 | -97.67 | 0.41 |
| 2026-07-14 | XTLB | 0.00 | -97.67 | 0.41 |
| 2026-07-15 | XTLB | 0.00 | -97.67 | 0.41 |
| 2026-07-16 | XTLB | 0.00 | -97.67 | 0.41 |
| 2026-07-17 | XTLB | 0.00 | -97.67 | 0.41 |
| 2026-07-20 | XTLB | 0.00 | -97.66 | 0.41 |
| 2026-07-21 | XTLB | 0.00 | -97.66 | 0.41 |
| 2026-07-22 | XTLB | 0.00 | -97.66 | 0.41 |
| 2026-07-23 | XTLB | 0.00 | -97.66 | 0.41 |
| 2026-07-24 | XTLB | 0.00 | -97.66 | 0.41 |
| 2026-07-27 | XTLB | 0.00 | -97.38 | 1.57 |
| 2026-07-28 | XTLB | 0.00 | -97.38 | 1.57 |
| 2026-07-29 | XTLB | 0.00 | -97.38 | 1.57 |
| 2026-07-30 | XTLB | 0.00 | -97.38 | 1.57 |
| 2026-07-31 | XTLB | 0.00 | -97.38 | 1.57 |
| 2026-08-03 | XTLB | 0.00 | -95.97 | 1.57 |
| 2026-08-04 | XTLB | 0.00 | -95.97 | 1.57 |
| 2026-08-05 | XTLB | 0.00 | -95.97 | 1.57 |
| 2026-08-06 | XTLB | 0.00 | -95.97 | 1.57 |
| 2026-08-07 | XTLB | 0.00 | -95.97 | 1.57 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
-95.97
Beta
1.4
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
2
Growth Score
Sentiment Score
37
Actual DrawDown %
87.3
Max Drawdown 5-Year %
-90.1
Target Price
6
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.02
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
XTLB
Healthcare
$2.94
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
56.2
Range 1M
60%
Sup Dist
6.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
0%
EPS NY
0%
52W%
9.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+104.1% upside
Upside
+104.1%
Quality
2
XTLB — P/E HistoricalBiotechnology
XTL Biopharmaceuticals Ltd.Sector: Healthcare
Industry: Biotechnology
Employees: 4
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
XTLB
Latest News
—
Caricamento notizie per XTLB…
stock quote shares XTLB – X.T.L. Biopharmaceuticals Ltd. ADR Stock Price stock today
news today XTLB – X.T.L. Biopharmaceuticals Ltd. ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch XTLB – X.T.L. Biopharmaceuticals Ltd. ADR yahoo finance google finance
stock history XTLB – X.T.L. Biopharmaceuticals Ltd. ADR invest stock market
stock prices XTLB premarket after hours
ticker XTLB fair value insiders trading